focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Warthog, you know the score chap.
The fundamentals have not changed the price is what it is until the next RNS for cohort increase.
The BOD have not communicated any bad news insofar and infact have advised ph1a is going well. It's a first in-human clinical trial and ph1a is a vital step to progression- so with that in mind take advantage of the low price because most are.
Remember 1st dosed 6th June, 11wks into ph1a, trial not stopped by the safety committee and Q3 earmarked for dose escalation to part 2 multi-ascending regime.
This period of lows will be seen as a blip in my opinion.
If it was a disaster the trial would have been stopped and no funding would have been secured in the first let alone 5m meaning a placing to raise funds to progress to ph1b which is Dr Readers gamechanging stage.
82.5p so what- I'm not shorting it or have a short open at 50p and sweating it get there before the next drop i.e. Q3 which is likely before the end of Sept.
This is top up territory as we will be multiples of this once the pk data is ready for ph1b.
Tell me bluenose- what the going rate on a ph2/3 ready combo proven compound for licence. I.e. what would the licence agreement likely to fetch and the upfront?
Lets see if you've been paying attention as the investor you claim to be.
Little brat 🤣- I believe I'm the wrong side of 40 to be labelled that.
Your not an investor sweetie- no investor s.. loads their investment and the very people who have made the company what it is today. Not too there was no hope of Saruem getting to clinic and the cash running out etc etc.
Now we are in clinic and have the investment to get to Dr Readers ph1b gamechanging phase and your still p.. and moaning and it's human trial with the safety committee in full control.
Every investor understands this and knows the timeline that matches such trials and the patience required and as someone put it disregard for shortermism- your no investor chappie pull the other one
Stranger things have happen- go cavelier I say.. Hi Ho Silver 😉
https://pubmed.ncbi.nlm.nih.gov/10736971/
Conclusions: Our results provide indirect evidence that insider trading may be common in the biotechnology industry.
Each subject will be in Part 1 for approximately 6 weeks (screening visit to follow-up visit). Part 2 (multiple ascending dose) is planned to commence after the Safety Review Committee (SRC) has evaluated the available data from at least Cohorts A, B, and C in Part 1.
That was from the 6th June 1st dose RNS- so the suspense que music....
"Pending the continuing good progress of the single ascending dose stage and review of the results by the safety review committee, we expect Part 2 of the trial, the multiple ascending dose, to commence in Q3 2023.
Let's see how things pan out. I for one am intrigued as to what the Safety Committee will announce as the normal cohort move as per the 1st dose RNS should have been run of the mill RNS.
We are 11wks in and indication for next cohort was 6wks.
The alternative would have been to do a placing at say 50p or the special death spiral price of 20p.
The fact we were offered £5mil is a huge mark of confidence that 1801 and the rest of the pipeline has promise. In fact I am sure River would have been shown up-to-date trial details before parting with any money.
Most certainly not in detail- I am going from RNS to RNS and have seen this sort of thing for many years on various shares.
We can only go by fact and from this we can gauge that no bad news has been reported by Sareum nothing has been pulled or stopped and the fist in-human trial is very much alive.
Until we are told otherwise the price can do what it wants- for investors the daily movement means nowt compared to what it will be come ph1b start as then w will have a dosage amount and clinical package to present to the pharma industry and go into hospital patients.
Pum and magy by then will be no where to be seen, stick around and I will do the I told you so thing.
I advised this would happen but then anyone could have to be honest. Let's just wait for the safety committee to give us the green light on the next cohort, 1st dosed on 6th June so well overdue- could they change the trial design if safety is excellent.
Ahfam3
Posted in:Â SAR
Posts:Â 3,416
Price:Â 97.50
No Opinion
RE: Wow16 Mar 2023 20:03
Nah Kool, it's precursor to Sealioning (uber c..womble types but worse). And as we get closer to and get to clinic and transform into a clinical stage company it will get worse.
Then as we go through ph1a, b, 2 etc. and progress through different cohorts etc. more of your type will turn up under the false pretence of balanced, reasoned debate etc, then claiming victimisation when your called out and so forth.
It's a long-term thing most are not invested and working for people or entities to short, lower entry etc. AIM is full of them and I have seen it for years on other shares boards for over 5yrs+.
Blue, I can see exactly what is going on and we are going to do a 20p placing as we have no news to come and the funding facility was just for the BOD to go on thr razz in the outback because magy pum say to so.
Now back in the real world RNS states chk1 is being looked after by cancer research. 1801 is awaiting safety committee green light to go to the next cohort.
So those 2 pieces of news will be coming with 1801 earmarked for Q3 as per the RNS and they will have a positive effect on the share price.
And when the chk1 licencing deal land then bye bye t...s
History will show that this downward event was but a blip in the price. As all previous events like this have been just noise.
The fact is we are a clinical stage company now so every move up in clinical progression i.e. cohort increase and ph1, 2 will have a hugely positive effect on the price.
So this is your last chance to get in at these low prices as before Q3 when the safety committee announce the next cohort increase in multi ascending trial.
Nothing we say or do on here will change anything other than sentiment towards each other. The facts are clear Sareum are clinical stage company now ph1a is a very important step as it shows how safe the capsule is.
It then sets up dosage and tolerance for ph1b and all future clinical trials in hospital patients and otherwise in Psoriasis and any other auto-immune illness a major may want to use it for.
The price will follow suit upon the hitting of ph1a data milestone and ph1b efficacy data which will be a major upward inflection point- that's if a major allows us to finish ph1b as it will increase the value of 1801 exponentially.
As we have seen from Citizens post today the Tyk2/Jak1 pathway is becoming groundbreaking and everyone wants a piece of it- but Dr Reader already knew that hence the last 2 patents which cross over and extend patent life.
The price is what it is until the next inflection point and that is in my opinion ph1b as with nearly all pharmas, however, publishing of ph1a data as above can also have a massive effect as the industry wants to see how safe 1801 is and at what dosage and tolerance future trials will take place with.
What a moron, so your telling us 50p by xmas and that no news will be announced until new year.
Complete nonsence, Chk1 news can drop at anytime and the last RNS advised next move on cohort in Q3.
We 1st dosed on 6th June and the Safety Committee has not stopped the trial- this for any investor is hugely significant and unpins the safety profile of 1801.
The move to next cohort will without doubt be a positive event as the dosage increases in a in-human trial.
Andy, what are you on about- puma, bluenose and funny have been down to the trial and checked it all out and have confirmed they're giving them all smarties hence this funding facility and death spiral.
The monies being used on a epic pub crawl in the outback